vs

Side-by-side financial comparison of Riley Exploration Permian, Inc. (REPX) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $97.3M, roughly 1.6× Riley Exploration Permian, Inc.). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -5.3%). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs -1.2%).

Riley Exploration Permian, Inc. is an independent energy company focused on exploration, development, and production of crude oil, natural gas, and natural gas liquids primarily in the US Permian Basin spanning Texas and New Mexico. It prioritizes cost-efficient onshore reserve development to supply reliable energy products to North American markets.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

REPX vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.6× larger
TARS
$151.7M
$97.3M
REPX
Growing faster (revenue YoY)
TARS
TARS
+133.7% gap
TARS
128.4%
-5.3%
REPX
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
-1.2%
REPX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
REPX
REPX
TARS
TARS
Revenue
$97.3M
$151.7M
Net Profit
$-8.4M
Gross Margin
Operating Margin
26.9%
-5.3%
Net Margin
-5.5%
Revenue YoY
-5.3%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$4.02
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
REPX
REPX
TARS
TARS
Q4 25
$97.3M
$151.7M
Q3 25
$106.9M
$118.7M
Q2 25
$85.4M
$102.7M
Q1 25
$102.5M
$78.3M
Q4 24
$102.7M
$66.4M
Q3 24
$102.3M
$48.1M
Q2 24
$105.4M
$40.8M
Q1 24
$99.7M
$27.6M
Net Profit
REPX
REPX
TARS
TARS
Q4 25
$-8.4M
Q3 25
$16.3M
$-12.6M
Q2 25
$30.5M
$-20.3M
Q1 25
$28.6M
$-25.1M
Q4 24
$-23.1M
Q3 24
$25.7M
$-23.4M
Q2 24
$33.5M
$-33.3M
Q1 24
$18.8M
$-35.7M
Operating Margin
REPX
REPX
TARS
TARS
Q4 25
26.9%
-5.3%
Q3 25
27.0%
-12.2%
Q2 25
33.7%
-21.6%
Q1 25
48.3%
-33.5%
Q4 24
31.2%
-36.8%
Q3 24
17.1%
-52.3%
Q2 24
50.9%
-81.6%
Q1 24
50.7%
-136.5%
Net Margin
REPX
REPX
TARS
TARS
Q4 25
-5.5%
Q3 25
15.3%
-10.6%
Q2 25
35.7%
-19.8%
Q1 25
27.9%
-32.1%
Q4 24
-34.8%
Q3 24
25.1%
-48.7%
Q2 24
31.8%
-81.6%
Q1 24
18.8%
-129.4%
EPS (diluted)
REPX
REPX
TARS
TARS
Q4 25
$4.02
$-0.17
Q3 25
$0.77
$-0.30
Q2 25
$1.44
$-0.48
Q1 25
$1.36
$-0.64
Q4 24
$0.52
$-0.57
Q3 24
$1.21
$-0.61
Q2 24
$1.59
$-0.88
Q1 24
$0.94
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
REPX
REPX
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$417.3M
Total DebtLower is stronger
$247.9M
$72.4M
Stockholders' EquityBook value
$634.2M
$343.4M
Total Assets
$1.2B
$562.2M
Debt / EquityLower = less leverage
0.39×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
REPX
REPX
TARS
TARS
Q4 25
$417.3M
Q3 25
$401.8M
Q2 25
$381.1M
Q1 25
$407.9M
Q4 24
$291.4M
Q3 24
$317.0M
Q2 24
$323.6M
Q1 24
$298.5M
Total Debt
REPX
REPX
TARS
TARS
Q4 25
$247.9M
$72.4M
Q3 25
$367.0M
$72.3M
Q2 25
$275.2M
$72.1M
Q1 25
$249.3M
$72.0M
Q4 24
$269.5M
$71.8M
Q3 24
$288.6M
$71.7M
Q2 24
$322.7M
$71.6M
Q1 24
$341.8M
$29.9M
Stockholders' Equity
REPX
REPX
TARS
TARS
Q4 25
$634.2M
$343.4M
Q3 25
$566.5M
$335.1M
Q2 25
$556.9M
$332.6M
Q1 25
$532.4M
$342.5M
Q4 24
$510.6M
$224.5M
Q3 24
$507.4M
$237.5M
Q2 24
$489.0M
$252.2M
Q1 24
$434.6M
$275.2M
Total Assets
REPX
REPX
TARS
TARS
Q4 25
$1.2B
$562.2M
Q3 25
$1.2B
$534.6M
Q2 25
$1.0B
$495.0M
Q1 25
$994.9M
$500.8M
Q4 24
$993.5M
$377.0M
Q3 24
$997.9M
$376.3M
Q2 24
$1.0B
$376.8M
Q1 24
$956.4M
$349.3M
Debt / Equity
REPX
REPX
TARS
TARS
Q4 25
0.39×
0.21×
Q3 25
0.65×
0.22×
Q2 25
0.49×
0.22×
Q1 25
0.47×
0.21×
Q4 24
0.53×
0.32×
Q3 24
0.57×
0.30×
Q2 24
0.66×
0.28×
Q1 24
0.79×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
REPX
REPX
TARS
TARS
Operating Cash FlowLast quarter
$64.9M
$19.3M
Free Cash FlowOCF − Capex
$13.0M
FCF MarginFCF / Revenue
8.6%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
REPX
REPX
TARS
TARS
Q4 25
$64.9M
$19.3M
Q3 25
$63.6M
$18.3M
Q2 25
$33.6M
$-29.4M
Q1 25
$50.4M
$-20.7M
Q4 24
$66.4M
$-22.2M
Q3 24
$72.1M
$-8.7M
Q2 24
$51.6M
$-14.4M
Q1 24
$56.1M
$-37.8M
Free Cash Flow
REPX
REPX
TARS
TARS
Q4 25
$13.0M
Q3 25
$16.3M
Q2 25
$-30.4M
Q1 25
$-21.2M
Q4 24
$-22.3M
Q3 24
$-8.9M
Q2 24
$-15.4M
Q1 24
$-38.0M
FCF Margin
REPX
REPX
TARS
TARS
Q4 25
8.6%
Q3 25
13.8%
Q2 25
-29.6%
Q1 25
-27.1%
Q4 24
-33.5%
Q3 24
-18.6%
Q2 24
-37.8%
Q1 24
-137.5%
Capex Intensity
REPX
REPX
TARS
TARS
Q4 25
4.2%
Q3 25
1.6%
Q2 25
1.0%
Q1 25
0.8%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
2.5%
Q1 24
0.6%
Cash Conversion
REPX
REPX
TARS
TARS
Q4 25
Q3 25
3.90×
Q2 25
1.10×
Q1 25
1.76×
Q4 24
Q3 24
2.81×
Q2 24
1.54×
Q1 24
2.99×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons